文献速递牙周病牙体牙髓病

微创非手术治疗用于骨丧失达根尖牙的临床与龈沟液结局:前瞻性研究

Clinical and GCF outcomes of Minimally-invasive non-surgical periodontal therapy in teeth with bone loss to the apex. A prospective study.
PubMed 文献 · J Dent · 2024-10-13

尽管临床和影像学指标显著改善,多数缺损在12个月时探诊深度(PPD)仍>5mm,需进一步治疗;龈沟液(GCF)中衰老分泌表型相关生物标志物在治疗后即刻升高、至12个月下降,IL-1β和MMP-3升高似与MINST后需牙髓治疗风险增加相关。

要点

  • MINST可降低PPD、获得临床附着水平(CAL)并减少影像学缺损深度。
  • 多数骨丧失达根尖的缺损在12个月时PPD仍>5mm,单独MINST常不足。
  • GCF中IL-1β和MMP-3升高可能与MINST后需牙髓治疗风险增加相关。

核心结论

  • 对预后不佳且骨丧失达根尖的患牙行MINST,12个月后PPD降低、CAL获得且影像学缺损深度减少。
  • 但多数此类病例单独MINST可能不足以实现缺损消退。

研究设计与样本

  • 所有患者接受包括MINST的步骤1和2牙周治疗,随访至治疗后12个月。
  • 在试验位点和对照位点收集临床参数、标准化根尖片和龈沟液样本,分析31种生物标志物。

主要发现

  • 尽管临床和影像学参数显著改善,多数缺损在12个月复评时PPD仍>5mm,需进一步治疗,部分病例需牙髓治疗。
  • 试验位点治疗后即刻检测到与衰老分泌表型相关的GCF生物标志物升高模式,至12个月下降。
  • IL-1β和MMP-3升高似与MINST后需牙髓治疗风险增加相关。
  • 3例未完成12个月复评(2例失访和1颗牙因折裂丧失)。

临床怎么用

  • 对骨丧失达根尖的患牙可考虑MINST以改善PPD、CAL和影像学缺损深度。
  • 应预期多数缺损需辅助治疗才能达到治疗终点,并评估牙髓治疗需求。
  • GCF生物标志物(如IL-1β和MMP-3)可能有助于阐明愈合模式。

局限性

  • 研究为前瞻性设计,未设置随机对照。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

AIMS: The aim of this prospective study was to assess the potential benefits of minimally-invasive non-surgical therapy (MINST) in the healing of intrabony defects reaching the apex. METHODS: Twenty systemically healthy patients with stage III-IV periodontitis and with at least one tooth with an intrabony defect reaching the apex were included in the study. Step 1 and 2 periodontal therapy including MINST were provided to all patients and patients were then followed up to 12 months post-treatment. Clinical parameters, standardised periapical radiographs and gingival crevicular fluid (GCF) samples were collected at test and control sites. 31 biomarkers were analysed. RESULTS: Three cases did not have the 12-months review (2 drop-outs and 1 tooth lost due to fracture). Despite significant improvements in clinical and radiographic parameters, the majority of defects still had PPD>5mm at the 12-months reassessment, therefore needing further treatment, including endodontic treatment in some cases. A pattern of increase in GCF biomarkers associated with a senescent secretory phenotype was detected immediately after treatment in test sites, with a decrease up to 12 months. An increase in IL-1β and MMP-3 in particular seems to be associated with increased risk to need endodontic treatment post-MINST. CONCLUSIONS: The treatment of teeth with unfavourable prognosis and bone loss to the apex with MINST leads to PPD reduction, CAL gain and reduction in radiographic defect depth 12 months after treatment. However, MINST alone may not be sufficient in terms of defects resolution in most of these cases. CLINICAL SIGNIFICANCE: The treatment of teeth with unfavorable prognosis and bone loss to the apex (hopeless) using MINST may lead to consistent PPD reduction, CAL gain and radiographic defect depth reduction after 12 months. However, adjunctive therapies may be necessary to achieve endpoints of therapy in these defects. GCF biomarkers may clarify healing patterns.

来源:J Dent,查看原文。版权归原作者所有。

引用

  1. Mainas G, Moore J, Patel A, et al. Clinical and GCF outcomes of Minimally-invasive non-surgical periodontal therapy in teeth with bone loss to the apex. A prospective study. J Dent. 2024. PMID: 39406279. doi:10.1016/j.jdent.2024.105403

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。